We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

99 hedge funds and large institutions have $749M invested in Lexicon Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 35 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 103 → 99 (-4)

8% less capital invested

Capital invested by funds: $813M → $749M (-$63.6M)

26% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 35

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
99
Holders Change
-4
Holders Change %
-3.88%
% of All Funds
2.85%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
26
Reduced
35
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$3.89M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.01M
3
UBS AM
UBS AM
Illinois
+$750K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$265K
5
Morgan Stanley
Morgan Stanley
New York
+$219K

Top Sellers

1
State Street
State Street
Massachusetts
-$6.17M
2
RA
Royce & Associates
New York
-$2.07M
3
BFA
BlackRock Fund Advisors
California
-$1.47M
4
CNB
City National Bank
California
-$841K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$507K
Name Holding Trade Value Shares
Change 		Change in
Stake
KFC
51
Klingenstein Fields & Co
New York
$193K – – –
Citadel Advisors
52
Citadel Advisors
Florida
$184K +$22.1K +2,057 +14%
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$165K -$123K -11,457 -44%
TC
54
TFS Capital
Pennsylvania
$143K +$136K +12,704 New
Goldman Sachs
55
Goldman Sachs
New York
$136K +$19.8K +1,841 +18%
Barclays
56
Barclays
United Kingdom
$125K +$74K +6,890 +63%
N
57
Nuveen
North Carolina
$89K – – –
U
58
UBS
Switzerland
$82K -$3.33K -310 -4%
Commonwealth Equity Services
59
Commonwealth Equity Services
Massachusetts
$79K +$22.3K +2,072 +42%
Public Employees Retirement Association of Colorado
60
Public Employees Retirement Association of Colorado
Colorado
$76K – – –
MAA
61
Managed Account Advisors
New Jersey
$75K +$15.3K +1,424 +27%
SG Americas Securities
62
SG Americas Securities
New York
$72K +$68.5K +6,381 New
RG
63
Rathbones Group
United Kingdom
$71K – – –
WB
64
WesBanco Bank
West Virginia
$67K – – –
CNB
65
City National Bank
California
$59K -$841K -78,340 -94%
Prudential Financial
66
Prudential Financial
New Jersey
$58K +$28.2K +2,628 +104%
Citigroup
67
Citigroup
New York
$48K -$129K -12,056 -74%
Tudor Investment Corp
68
Tudor Investment Corp
Connecticut
$40K – – –
PA
69
Profund Advisors
Maryland
$38K +$709 +66 +2%
TTWM
70
TCV Trust & Wealth Management
Virginia
$37K – – –
Wells Fargo
71
Wells Fargo
California
$35K +$32.4K +3,020 +2,112%
AB
72
Amalgamated Bank
New York
$33K -$2.69K -250 -8%
Los Angeles Capital Management
73
Los Angeles Capital Management
California
$32K -$396K -36,855 -93%
GC
74
Guggenheim Capital
Illinois
$31K -$2.4K -223 -8%
VFA
75
Virtus Fund Advisers
Connecticut
$31K +$29.9K +2,786 New
1 2
3
4 5

LXRX Hedge Fund Activity: Q2 2014 in Review

99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2014, worth a combined $749M — down 7.8% from $813M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of LXRX and 8 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 26 added.

The largest buyer was Norges Bank, adding an estimated $3.89M. The largest seller was State Street, cutting an estimated $6.17M.

  • 99 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2014, down from 103 in Q1 2014.
  • Funds reported $749M of Lexicon Pharmaceuticals stock for Q2 2014, down 7.8% quarter-over-quarter.
  • 8 funds opened new Lexicon Pharmaceuticals positions in Q2 2014 and 12 closed out, a net change of -4 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q2 2014 was Norges Bank, an estimated $3.89M added.
  • The largest Lexicon Pharmaceuticals seller in Q2 2014 was State Street, an estimated $6.17M sold.

Based on aggregated 13F filings for Q2 2014.